Table II.
Differences between patients who were and were not diagnosed with MM during FU
| MM during follow-up | p-value | OR | 95% CI | ||||
|---|---|---|---|---|---|---|---|
| No (N=540) | Yes (N=78) | ||||||
| n | % | n | % | ||||
| Sex | 0.020 | ||||||
| Female | 304 | 56.3 | 33 | 42.3 | 1.00 | (Reference) | |
| Male | 236 | 43.7 | 45 | 57.7 | 1.76 | (1.09–2.84) | |
| Age at inclusion | 0.001 | ||||||
| 0–20 | 51 | 9.4 | 5 | 6.4 | 1.00 | (Reference) | |
| 21–40 | 295 | 54.6 | 31 | 39.7 | 1.07 | (0.40–2.89) | |
| 41–60 | 171 | 31.7 | 31 | 39.7 | 1.85 | (0.68–5.00) | |
| >60 | 23 | 4.3 | 11 | 14.1 | 4.88 | (1.52–15.66) | |
| AMS | 0.636 | ||||||
| No | 53 | 9.8 | 9 | 11.5 | 1.00 | (Reference) | |
| Yes | 487 | 90.2 | 69 | 88.5 | 0.83 | (0.39–1.77) | |
| Previous melanoma | <0.001 | ||||||
| No | 317 | 58.7 | 24 | 30.8 | 1.00 | (Reference) | |
| Yes | 223 | 41.3 | 54 | 69.2 | 3.20 | (1.92–5.33) | |
| Previous multiple melanoma | 0.003 | ||||||
| No | 484 | 89.6 | 61 | 78.2 | 1.00 | (Reference) | |
| Yes | 56 | 10.4 | 17 | 21.8 | 2.41 | (1.32–4.41) | |
| Number of melanoma previous to beginning | 0.070 | ||||||
| 1 | 165 | 74.3 | 37 | 68.5 | 1.00 | (Reference) | |
| 2 | 49 | 22.1 | 10 | 18.5 | 0.91 | (0.42–1.96) | |
| 3 | 5 | 2.3 | 3 | 5.6 | 2.68 | (0.61–11.70) | |
| 4 | 2 | 0.9 | 2 | 3.7 | 4.46 | (0.61–32.69) | |
| 5 | 1 | 0.5 | 2 | 3.7 | 8.92 | (0.79–100.98) | |
| Nevi count | 0.058 | ||||||
| < 50 | 40 | 7.4 | 4 | 5.1 | 1.00 | (Reference) | |
| 50–100 | 200 | 37.0 | 18 | 23.1 | 0.90 | (0.29–2.80) | |
| 100–200 | 204 | 37.8 | 37 | 47.4 | 1.81 | (0.61–5.37) | |
| > 200 | 96 | 17.8 | 19 | 24.4 | 1.98 | (0.63–6.19) | |
| More than 100 nevus | 0.007 | ||||||
| No | 240 | 44.4 | 22 | 28.2 | 1.00 | (Reference) | |
| Yes | 300 | 55.6 | 56 | 71.8 | 2.04 | (1.21–3.43) | |
| Phototype | 0.422 | ||||||
| I | 15 | 2.8 | 4 | 5.1 | 1.00 | (Reference) | |
| II | 219 | 40.6 | 30 | 38.5 | 0.51 | (0.16–1.65) | |
| III | 284 | 52.6 | 43 | 55.1 | 0.57 | (0.18–1.79) | |
| IV | 22 | 4.1 | 1 | 1.3 | 0.17 | (0.02–1.68) | |
| Phototype | 0.966 | ||||||
| I–II | 234 | 43.3 | 34 | 43.6 | 1.00 | (Reference) | |
| III–IV | 306 | 56.7 | 44 | 56.4 | 0.99 | (0.61–1.60) | |
| Lentigines | 0.286 | ||||||
| No | 214 | 39.6 | 26 | 33.3 | 1.00 | (Reference) | |
| Yes | 326 | 60.4 | 52 | 66.7 | 1.31 | (0.80–2.17) | |
| Excised lesions | <0.001 | ||||||
| 0 | 211 | 39.1 | 0 | 0.0 | - | - | |
| 1 | 135 | 25.0 | 14 | 18.0 | 1,00 | (Reference) | |
| 2 | 70 | 13.0 | 14 | 18.0 | 1,93 | (0.87–4.27) | |
| 3 | 50 | 9.3 | 14 | 18.0 | 2,70 | (1.20–6.06) | |
| 4 | 35 | 6.5 | 9 | 11.5 | 2,48 | (0.99–6.20) | |
| 5 | 15 | 2.8 | 5 | 6.4 | 3,21 | (1.02–10.17) | |
| 6 | 10 | 1.9 | 7 | 9.0 | 6,75 | (2.22–20.52) | |
| >=7 | 14 | 2.6 | 15 | 19.2 | 10,33 | (4.15–25.74) | |
| CDKN2A | <0.001 | ||||||
| Negative | 239 | 44.3 | 61 | 78.2 | 1.00 | (Reference) | |
| not performed | 272 | 50.4 | 7 | 9.0 | 0.10 | (0.05–0.22) | |
| Positive | 29 | 5.4 | 10 | 12.8 | 1.35 | (0.62–2.92) | |
| mean | (SD) | mean | (SD) | p-value | OR | 95% CI | |
| Age at inclusion | 36.2 | (12.8) | 42.4 | (15.5) | <0.001 | 1.03 | (1.02–1.05) |
| Number of controlled lesions | 17.6 | (8.2) | 24.2 | (13.0) | <0.001 | 1.07 | (1.04–1.09) |
| number of excised lesions | 1.5 | (1.9) | 4.3 | (3.5) | <0.001 | 1.50 | (1.35–1.66) |
| Length of follow-up (months) | 85.3 | (29.9) | 88.8 | (31.0) | 0.348 | 1.00 | (1.00–1.01) |
AMS: Atypical Mole Syndrome